A. Machens, U. Schneyer, H. Holzhausen, and H. Dralle, Prospects of Remission in Medullary Thyroid Carcinoma According to Basal Calcitonin Level, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.4, pp.2029-2034, 2005.
DOI : 10.1210/jc.2004-1836

S. Wells, S. Asa, and H. Dralle, Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, Thyroid, vol.25, issue.6, pp.567-610, 2015.
DOI : 10.1089/thy.2014.0335

M. Luster, W. Karges, and K. Zeich, Clinical Value of 18-Fluorine-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography in the Follow-Up of Medullary Thyroid Carcinoma, Thyroid, vol.20, issue.5, pp.527-533, 2010.
DOI : 10.1089/thy.2009.0342

S. Kauhanen, C. Schalin-jäntti, and M. Seppänen, Complementary Roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in Medullary Thyroid Cancer, Journal of Nuclear Medicine, vol.52, issue.12, pp.1855-1863, 2011.
DOI : 10.2967/jnumed.111.094771

A. Oudoux, P. Salaun, and C. Bournaud, Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.12, pp.4590-4597, 2007.
DOI : 10.1210/jc.2007-0938

H. Verbeek, J. Plukker, and K. Koopmans, Clinical Relevance of 18F-FDG PET and 18F-DOPA PET in Recurrent Medullary Thyroid Carcinoma, Journal of Nuclear Medicine, vol.53, issue.12, pp.1863-1871, 2012.
DOI : 10.2967/jnumed.112.105940

P. Peltier, C. Curtet, and J. Chatal, Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium- 111-labeled DTPA dimer, J Nucl Med, vol.34, pp.1267-1273, 1993.

J. Barbet, P. Peltier, and S. Bardet, Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA · anti-DTPA-indium bispecific antibody, J Nucl Med, vol.39, pp.1172-1178, 1998.

A. Wu, Antibodies and Antimatter: The Resurgence of Immuno-PET, Journal of Nuclear Medicine, vol.50, issue.1, pp.2-5, 2009.
DOI : 10.2967/jnumed.108.056887

O. Boerman and W. Oyen, Immuno-PET of Cancer: A Revival of Antibody Imaging, Journal of Nuclear Medicine, vol.52, issue.8, pp.1171-1172, 2011.
DOI : 10.2967/jnumed.111.089771

E. Rossi, D. Goldenberg, T. Cardillo, W. Mcbride, R. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proceedings of the National Academy of Sciences, vol.103, issue.18, pp.6841-6846, 2006.
DOI : 10.1073/pnas.0600982103

W. Mcbride, P. Zanzonico, and R. Sharkey, Bispecific antibody pretargeting PET (immunoPET) with an 124 I-labeled hapten-peptide, J Nucl Med, vol.47, pp.1678-1688, 2006.

R. Schoffelen, R. Sharkey, and D. Goldenberg, Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts, Molecular Cancer Therapeutics, vol.9, issue.4, pp.1019-1027, 2010.
DOI : 10.1158/1535-7163.MCT-09-0862

R. Schoffelen, O. Boerman, and D. Goldenberg, Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, British Journal of Cancer, vol.20, issue.4, pp.934-942, 2013.
DOI : 10.1038/bjc.2013.376

R. Schoffelen, W. Woliner-van-der-weg, and E. Visser, Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.Suppl 1, pp.1593-1602, 2014.
DOI : 10.1007/s00259-014-2742-6

F. Kraeber-bodéré, C. Rousseau, and C. Bodet-milin, Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131 I-labeled bivalent hapten in a phase I optimization clinical trial, J Nucl Med, vol.47, pp.247-255, 2006.

C. Bodet-milin, L. Ferrer, and A. Rauscher, Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients, Frontiers in Medicine, vol.38, issue.12, p.84, 2015.
DOI : 10.1007/s00259-011-1903-0
URL : https://hal.archives-ouvertes.fr/hal-01258870

W. Mcbride, R. Sharkey, and H. Karacay, A Novel Method of 18F Radiolabeling for PET, Journal of Nuclear Medicine, vol.50, issue.6, pp.991-998, 2009.
DOI : 10.2967/jnumed.108.060418

K. Tamura, H. Kurihara, and K. Yonemori, 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer, Journal of Nuclear Medicine, vol.54, issue.11, pp.1869-1875, 2013.
DOI : 10.2967/jnumed.112.118612

R. Sharkey, W. Mcbride, and H. Karacay, A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res, vol.63, pp.354-363, 2003.
DOI : 10.2172/898305

M. Andersson, L. Johansson, D. Minarik, S. Leide-svegborn, and S. Mattsson, Erratum to: Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors, EJNMMI Physics, vol.2, issue.1, p.9, 2014.
DOI : 10.1186/s40658-015-0121-4

E. Dijkers, O. Munnink, T. Kosterink, and J. , Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer, Clinical Pharmacology & Therapeutics, vol.87, issue.5, pp.586-592, 2010.
DOI : 10.1162/153535003322556877

R. Baum, V. Prasad, and D. Müller, Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules, Journal of Nuclear Medicine, vol.51, issue.6, pp.892-897, 2010.
DOI : 10.2967/jnumed.109.073239